Modulation of Anxiolytic-Like and Antidepressant-Like Effects of Melatonin by Imipramine in Wistar Rats: Possible Interaction with Central Monoaminergic Systems
Our current study aims to explore the interaction of melatonin (MEL) with the monoaminergic system on the pathophysiology of affective disorders in Wistar rats. We mention here that, the role of monoaminergic transmission in the pathophysiology of affective disorders in humans is demonstrated in most recent reports. In this sense, our current work aims to explore the effect of melatonin (MEL) with or without imipramine (IMP) on levels of depression and anxiety in Wistar rats and would determine the role of MEL in modulating serotonin, noradrenaline and dopamine neurotransmission. From this point, twenty-four female Wister rats were divided into 4 groups of 6 animals and received subcutaneously during 4 weeks different doses of MEL (4 mg/kg), IMP (2 mg/kg) or MEL (4 mg/kg) + IMP (2 mg/kg). Behavioral performance especially anxiety and depression is measured in the open field (OFT), elevated plus maze (EPM) and forced swim test (FST). The anxiety-like and antidepressant-like effects were observed with MEL at 4 mg/Kg and IMP at 2 mg/Kg but the potentiating effect was more observed with the two combined molecules (MEL and IMP), since locomotors activity assessed by the OFT and EPM was not affected. These effects suggest that psychopharmacological actions of MEL are due, at least in part, to its ability to potentiate the central monoaminergic transmitter effects.
References
[1]
Boulenger, J.P., Fournier, M., Rosales, D. and Lavallee, Y.J. (1997) Mixed Anxiety and Depression: From Theory to Practice. Journal of Clinical Psychiatry, 58, 27-34.
https://doi.org/10.4088/JCP.v58n0107
[2]
Paul, S.M., Rehavi, M., Skolnick, P. and Al, E. (1981) Depressed Patients Have Decreased Binding of Titiated Imipramine to Platelet Serotonin “Transporter”. Archives of General Psychiatry, 38, 1315-1317.
https://doi.org/10.1001/archpsyc.1981.01780370017001
[3]
McIntyre, I.M., Judd, F.K., Marriott, P.M., Burrows, G.D. and Norman, T.R. (1989) Plasma Melatonin Levels in Affective States. International Journal of Clinical Pharmacology Research, 9, 159-164. http://europepmc.org/abstract/MED/2714920
[4]
Brown, R., Kocsis, J.H., Caroff, S., Amsterdam, J., Winokur, A., Stokes, P.E. and Frazer, A. (1985) Differences in Nocturnal Melatonin Secretion between Melancholic Depressed Patients and Control Subjects. American Journal of Psychiatry, 142, 811-816. https://doi.org/10.1176/ajp.142.7.811
[5]
Bourin, M., Mocaër, E. and Porsolt, R. (2004) Antidepressant-Like Activity of S 20098 (Agomelatine) in the Forced Swimming Test in Rodents: Involvement of Melatonin and Serotonin Receptors. Journal of Psychiatry & Neuroscience, 29, 126-133.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC383344
[6]
Wong, P.T.-H. and Ong, Y.P. (2001) Acute Antidepressant-Like and Antianxiety-Like Effects of Tryptophan in Mice. Pharmacology, 62, 151-156.
https://doi.org/10.1159/000056088
https://www.karger.com/DOI/10.1159/000056088
[7]
Sokolovic, D., Djordjevic, B., Kocic, G., Babovic, P., Ristic, G., Stanojkovic, Z., Sokolovic, D.M., Veljkovic, A., Jankovic, A. and Radovanovic, Z. (2012) The Effect of Melatonin on Body Mass and Behaviour of Rats during an Exposure to Microwave Radiation from Mobile Phone. Bratislavské lekárske listy, 113, 265-269.
http://europepmc.org/abstract/MED/22616582
https://doi.org/10.4149/BLL_2012_062
[8]
Shaji, A.V. and Kulkarni, S.K. (1998) Central Nervous System Depressant Activities of Melatonin in Rats and Mice. Indian Journal of Experimental Biology, 36, 257-263.
[9]
Richelson, E. and Pfenning, M. (1984) Blockade by Antidepressants and Related Compounds of Biogenic Amine Uptake into Rat Brain Synaptosomes: Most Antidepressants Selectively Block Norepinephrine Uptake. European Journal of Pharmacology, 104, 277-286. https://doi.org/10.1016/0014-2999(84)90403-5
[10]
Gentsch, C., Lichtsteiner, M. and Feer, H. (1987) Open Field and Elevated Plus-Maze: A Behavioural Comparison between Spontaneously Hypertensive (SHR) and Wistar-Kyoto (WKY) Rats and the Effects of Chlordiazepoxide. Behavioural Brain Research, 25, 101-107. https://doi.org/10.1016/0166-4328(87)90003-9
[11]
Naranjo-Rodriguez, E.B., Osornio, A.O., Hernandez-Avitia, E., Mendoza-Fernandez, V. and Escobar, A. (2000) Anxiolytic-Like Actions of Melatonin, 5-Metoxytryptophol, 5-Hydroxytryptophol and Benzodiazepines on a Conflict Procedure. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 24, 117-129.
https://doi.org/10.1016/S0278-5846(99)00075-5
[12]
Porsolt, R.D., Anton, G., Blavet, N. and Jalfre, M. (1978) Behavioural Despair in Rats: A New Model Sensitive to Antidepressant Treatments, European Journal of Pharmacology, 47, 379-391. https://doi.org/10.1016/0014-2999(78)90118-8
[13]
El Mrabet, F., Ouakki, S., Mesfioui, A., El Hessni, A. and Ouichou, A. (2012) Pinealectomy and Exogenous Melatonin Regulate Anxiety-Like and Depressive-Like Behaviors in Male and Female Wistar Rats. Neuroscience and Medicine, 3, 394-403.
https://doi.org/10.4236/nm.2012.34049
[14]
Ouakki, S., El Mrabet, F., Mesfioui, A., El Hessni, A. and Ouichou, A. (2013) Interaction Evidence of Melatonin and Hydroxyzine on the Level of Anxiety-Like and Depression-Like in Male and Female Rats. Science Library, 5, 2111-4706.
[15]
Karakaş, A., Coşkun, H., Kaya, A., Kücük, A. and Gündüz, B. (2011) The Effects of the Intraamygdalar Melatonin Injections on the Anxiety like Behavior and the Spatial Memory Performance in Male Wistar Rats. Behavioural Brain Research, 222, 141-150. https://doi.org/10.1016/j.bbr.2011.03.029
[16]
Detanico, B.C., Piato, Â.L., Freitas, J.J., Lhullier, F.L., Hidalgo, M.P., Caumo, W. and Elisabetsky, E. (2009) Antidepressant-Like Effects of Melatonin in the Mouse Chronic Mild Stress Model. European Journal of Pharmacology, 607, 121-125.
https://doi.org/10.1016/j.ejphar.2009.02.037
[17]
Ergun, Y., Orhan, F.O. and Karaaslan, M.F. (2008) Combination Therapy of Imipramine and Melatonin: Additive Antidepressant Effect in Mouse Forced Swimming Test. European Journal of Pharmacology, 591, 159-163.
https://doi.org/10.1016/j.ejphar.2008.06.070
[18]
Gorzalka, B.B., Brotto, L.A. and Hong, J.J. (1999) Corticosterone Regulation of 5-HT2A Receptor-Mediated Behaviors: Attenuation by Melatonin. Physiology & Behavior, 67, 439-442. https://doi.org/10.1016/S0031-9384(99)00096-7
[19]
Hanoun, N., Mocaer, E., Boyer, P.-A., Hamon, M. and Lanfumey, L. (2004) Differential Effects of the Novel Antidepressant Agomelatine (S 20098) versus Fluoxetine on 5-HT1A Receptors in the Rat Brain. Neuropharmacology, 47, 515-526.
https://doi.org/10.1016/j.neuropharm.2004.06.003
[20]
Micale, V., Arezzi, A., Rampello, L. and Drago, F. (2004) Melatonin Affects the Immobility Time of Rats in the Forced Swim Test: The Role of Serotonin Neurotransmission. European Neuropsychopharmacology, 16, 538-545.
https://doi.org/10.1016/j.euroneuro.2006.01.005
[21]
Fava, M., Targum, S.D., Nierenberg, A.A., Bleicher, L.S., Carter, T.A., Wedel, P.C., Hen, R., Gage, F.H. and Barlow, C. (2012) An Exploratory Study of Combination Buspirone and Melatonin SR in Major Depressive Disorder (MDD): A Possible Role for Neurogenesis in Drug Discovery. Journal of Psychiatric Research, 46, 1553-1563.
https://doi.org/10.1016/j.jpsychires.2012.08.013
[22]
Sibille, E., Sarnyai, Z., Benjamin, D., Gal, J., Baker, H. and Toth, M. (1997) Antisense Inhibition of 5-Hydroxytryptamine 2a Receptor Induces an Antidepressant-Like Effect in Mice. Molecular Pharmacology, 52, 1056-1063.
https://doi.org/10.1124/mol.52.6.1056
[23]
Monnet, F.P. (2002) Melatonin Modulates [3H] Serotonin Release in the Rat Hippocampus: Effects of Circadian Rhythm. Journal of Neuroendocrinology, 14, 194-199.
https://doi.org/10.1046/j.0007-1331.2001.00761.x
[24]
Millan, M.J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J.-M. and Cussac, D. (2003) The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine 2c Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways. Journal of Pharmacology and Experimental Therapeutics, 306, 954-964.
https://doi.org/10.1124/jpet.103.051797
[25]
Wood, M.D., Thomas, D.R. and Watson, J.M. (2002) Therapeutic Potential of Serotonin Antagonists in Depressive Disorders. Expert Opinion on Investigational Drugs, 11, 457-467. https://doi.org/10.1517/13543784.11.4.457
[26]
Pjrek, E., Winkler, D., Konstantinidis, A., Willeit, M., Praschak-Rieder, N. and Kasper, S. (2007) Agomelatine in the Treatment of Seasonal Affective Disorder. Psychopharmacology, 190, 575-579. https://doi.org/10.1007/s00213-006-0645-3
[27]
Rouillon, F. (2006) Efficacy and Tolerance Profile of Agomelatine and Practical Use in Depressed Patients. International Clinical Psychopharmacology, 21, S31-S35.
https://doi.org/10.1097/01.yic.0000195659.99148.09
[28]
Montgomery, S.A. (2006) Major Depressive Disorders: Clinical Efficacy and Tolerability of Agomelatine, a New Melatonergic Agonist. European Neuropsychopharmacology, 16, S633-S638. https://doi.org/10.1016/S0924-977X(06)70009-8
[29]
Domínguez-López, S., Mahar, I., Bambico, F.R., Labonté, B., Ochoa-Sánchez, R., Leyton, M. and Gobbi, G. (2012) Short-Term Effects of Melatonin and Pinealectomy on Serotonergic Neuronal Activity across the Light-Dark Cycle. Journal of Psychopharmacology, 26, 830-844. https://doi.org/10.1177/0269881111408460
[30]
de Gandarias, J.M., Echevarria, E., Acebes, I., Silio, M. and Casis, L. (1998) Effects of Imipramine Administration on Mu-Opioid Receptor Immunostaining in the Rat Forebrain. Arzneimittel Forschung, 48, 717-719.
http://europepmc.org/abstract/MED/9706370
[31]
Zisapel, N. (2001) Melatonin-Dopamine Interactions: From Basic Neurochemistry to a Clinical Setting. Cellular and Molecular Neurobiology, 21, 605-616.
https://doi.org/10.1023/A:1015187601628
[32]
Binfaré, R.W., Mantovani, M., Budni, J., Santos, A.R.S. and Rodrigues, A.L.S. (2010) Involvement of Dopamine Receptors in the Antidepressant-Like Effect of Melatonin in the Tail Suspension Test. European Journal of Pharmacology, 638, 78-83.
https://doi.org/10.1016/j.ejphar.2010.04.011